HOME - AnGes,Inc.

2019.03.26	AnGes Obtains Conditional Approval in Japan for HGF Gene Therapy to Treat Critical Limb Ischemia

2019.02.21	Japanese approval of HGF gene therapy drug, as the first gene therapy product to be launched in Japan

2019.02.12	AnGes and Kamada entered into agreement for the commercialization of HGF gene therapy product in Israel

2018.04.12	AnGes Announces First Patient Treated with DNA Vaccine for Hypertension in Phase I / II Clinical Study in Australia

2018.02.27	AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain

2018.01.22	AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia

2017.04.25	AnGes Announces FDA Clearance of Investigational New Drug (IND) Application for NF-kappaB decoy oligo DNA to treat discogenic lower back pain

2019.02.22	Notice of Convocation Annual General Meeting 2019

2018.02.23	Notice of Convocation Annual General Meeting 2018

2018.02.02	Consolidated Financial Report for 2017

2017.03.02	Notice of Convocation Annual General Meeting 2017

2017.02.03	Consolidated Financial Report for 2016